Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Hyperandrogenism Versus Insulin Resistance in Infertile Polycystic Ovary Syndrome (PCOS) Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Couples Inclusion Criteria:~* Partner with sperm concentration of \>=14 million/mL in at least one ejaculate with motile sperm.~* Ability to have regular intercourse 2-3 times per week during the ovulation induction phase of study.~* At least one patent tube and normal uterine cavity as determined by sonohysterogram, hysterosalpingogram, or hysteroscopy/laparoscopy within the last 3 years, or confirmation of a intrauterine pregnancy within the past 2 years.~* No previous sterilization procedures(vasectomy, tubal ligation) that have been reversed.~* Wanting to seek pregnancy.~Inclusion Criteria:~* Chronic anovulation or oligomenorrhea defined as intermenstrual periods of \>= 45 days or a total of \<=8 periods per year.~* Hyperandrogenism will be an elevated total testosterone \>=50 ng/dL.~* Hirsutism determined by a modified Ferriman-Gallwey Score \>8.~* PCO on ultrasound (12 or more follicles measuring 2-9 mm in diameter).~* BMI \>=27 to \<=42.~* Normal EKG to rule out any abnormalities with the heart.~Exclusion Criteria:~* Current pregnancy.~* Patients on oral contraceptives, depo progestins, or hormonal implants.~* Patients with hyperprolactinemia defined as two prolactin levels at least one week apart \>30 ng/mL.~* Patients with known 21-hydroxylase deficiency by a fasting 17-hydroxyprogesterone (17-OHP) level \<2 ng/mL and ACTH stimulation test as needed, or other enzyme deficiency.~* Patients with menopausal FSH levels \>20 mIU/mL.~* Patients with uncorrected thyroid disease (TSH \<0.45 mIU/ML or \>4.5 mIU/ML).~* Patients diagnosed with Type1 or Type II diabetes.~* Patients with liver disease defined as AST or ALT \>2 times normal or total bilirubin \>2.5 mg/dL.~* Patients with renal disease defined as BUN \>30 mg/dL or serum creatinine \>1.4 mg/dL.~* Patients with significant anemia (Hemoglobin \<10 mg/dL).~* Patients with a history of deep venous thrombosis, pulmonary embolus, or cerebrovascular accident.~* Patients with known heart disease that is likely to be exacerbated by pregnancy.~* Patients with a history of , or suspected cervical carcinoma, endometrial carcinoma, or breast carcinoma. A normal PAP smear or reassuring colposcopy based on current ACOG guidelines will be required.~* Patient with current history of alcohol abuse.~* Patients enrolled simultaneously into other investigative studies.~* Patients taking other medications know to affect reproductive function or metabolism.~* Patients with a suspected adrenal or ovarian tumor secreting androgens.~* Patients with suspected Cushing's syndrome.~* Patients who have undergone a bariatric surgery procedure in the recent past (\<12 months).~* Patients with untreated poorly controlled hypertension defined as systolic blood pressure \>=150 mm Hg or average diastolic \>=100 mm Hg on three measurements obtained 5 minutes apart. If treated, average systolic blood pressure \>= 140 mm Hg or average diastolic \>= 90 mm Hg.~* Patients with medical conditions that represent contraindications to orlistat, OCP, clomiphene, and/or pregnancy.~* Patients currently participating in lifestyle intervention program (Weight Watchers, Atkins Diet, Curves) or lost more than 5% body weight within the last 6 months.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Lifestyle intervention (Type: ACTIVE_COMPARATOR): Orlistat/Meal Replacement/Lifestyle Modification
- Oral Contraceptives (OCP) (Type: ACTIVE_COMPARATOR): Loestrin 1/20
- Lifestyle/OCP Combined (Type: ACTIVE_COMPARATOR): Combination of treatments

Based on this trial design, predict the completion outcome and termination type (if applicable).